cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1049Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESЭндотелиальная дисфункция при артериальной гипертензии – фактор риска сердечно-сосудистых осложненийEndothelial dysfunction in arterial hypertension - cardiovascular complication risk factorНамакановБ. А.NamakanovB. A.РасуловМ. М.RasulovM. M.Московский городской педагогический университет, МоскваMoscow State Pedagogical University, Moscow20052012200546, ч.II98101Copyright © Намаканов Б.А., Расулов М.М., 20052005Намаканов Б.А., Расулов М.М.Namakanov B.A., Rasulov M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1049

В обзоре представлены результаты изучения патофизиологических основ эндотелиальной функции (ЭФ) и методов ее исследования в клинике; сопоставляются основные нейрогормональные механизмы регуляции ЭФ у здорового человека. Подробно разбираются диагностическое и прогностическое значения показателей нарушения ЭФ в качестве предиктора сердечно-сосудистых осложнений. Приведены современные данные о фармакологической и нефармакологической коррекции нарушений ЭФ у больных. Высказана точка зрения о генетической предрасположенности нарушений ЭФ у человека.

This review contains the results of the studies in pathophysiological basis of endothelial function (EF), and clinical methods for its assessment. Main neurohormonal mechanisms of EF regulation in healthy persons are compared. Diagnostic and prognostic value of EF disturbances, as cardiovascular event predictors, is analyzed in details. Modern data on pharmaceutical and non-pharmaceutical EF correction are presented. The authors also deliver a hypothesis on genetic causes for EF disturbances in humans.

функция эндотелиясердечно-сосудистые осложненияфакторы рискаингибиторы ангиотензин-превращающего ферментаendothelial functioncardiovascular complicationsrisk factorsACE inhibitorsReferencesАгеев Ф.Т. Овчинников А.Г. Мареев В.Ю. Беленков Ю.Н. Эндотелиальная дисфункция и сердечная недостаточность. Cons med 2001; 3(2): 61-5.Агеев Ф.Т. Овчинников А.Г. Мареев В.Ю. Беленков Ю.Н. Эндотелиальная дисфункция и сердечная недостаточность. Cons med 2001; 3(2): 61-5.Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1995; 25: 1135-43.Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1995; 25: 1135-43.Cottone S, Vadala A, Mangano MT. Endolelial factors in essential hypertension with microalbuminuria. Am J Hypertens 2000;13: 172-6.Cottone S, Vadala A, Mangano MT. Endolelial factors in essential hypertension with microalbuminuria. Am J Hypertens 2000;13: 172-6.Ferrari R, Bachetti T, Giurdigli G, et al. Bradikinin and coronary artery disease. Eur Heart J 2000; 2(Suppl.H): H14-9.Ferrari R, Bachetti T, Giurdigli G, et al. Bradikinin and coronary artery disease. Eur Heart J 2000; 2(Suppl.H): H14-9.Bernal E, Ugalde-Caristrot A, Sanchez O, Bajo-Martinez A. Endotelial Dysfunction Associated with the peak level of 24- hour mean blood pressure. J Hypertens 2004; 22(Suppl.2): S195.Bernal E, Ugalde-Caristrot A, Sanchez O, Bajo-Martinez A. Endotelial Dysfunction Associated with the peak level of 24- hour mean blood pressure. J Hypertens 2004; 22(Suppl.2): S195.Badilia E, Bartos D, Dorobantu M. Endotelial dysfunction evolution in hypertensive patients treated with nebivolol versus metoprolol. J Hypertens 2004; 22(Suppl. 2): S327.Badilia E, Bartos D, Dorobantu M. Endotelial dysfunction evolution in hypertensive patients treated with nebivolol versus metoprolol. J Hypertens 2004; 22(Suppl. 2): S327.Akkaya V, Erk O, Demirel S. Genetic predisposition to endothelial dysfunction in essential hypertension: a controlled study. J Hypertens 2004; 22(Suppl 2): S329.Akkaya V, Erk O, Demirel S. Genetic predisposition to endothelial dysfunction in essential hypertension: a controlled study. J Hypertens 2004; 22(Suppl 2): S329.Widimsky I, Petrak O, Mrazkovas J. High levels of markers of endothelial dysfunction in pheochromocytoma. J Hypertens 2004; 22 (Suppl 2): S184.Widimsky I, Petrak O, Mrazkovas J. High levels of markers of endothelial dysfunction in pheochromocytoma. J Hypertens 2004; 22 (Suppl 2): S184.Larroussue M, Bragulat E, Segarra M. Adhesion molecules, metalloproteinases and endothelial dysfunction in essential hypertension. J Hypertens 2004; 22(Suppl. 2): S191.Larroussue M, Bragulat E, Segarra M. Adhesion molecules, metalloproteinases and endothelial dysfunction in essential hypertension. J Hypertens 2004; 22(Suppl. 2): S191.Delles C, Lee WK, John S, Scmeider RE. A single nucleotide polymorphism (SNP) in the human glutathion S-transferase MU type 4 gene (GSTM 4) is asssociated with impaired endothelial function and arterial hypertension. J Hypertens 2004; 22(Suppl. 2): S212.Delles C, Lee WK, John S, Scmeider RE. A single nucleotide polymorphism (SNP) in the human glutathion S-transferase MU type 4 gene (GSTM 4) is asssociated with impaired endothelial function and arterial hypertension. J Hypertens 2004; 22(Suppl. 2): S212.Makris Th, Papazachou O, Papadopoulos D. Circadian rhythm affects unfavourably haemostasis balance parameters in untreated hypertensive patients. J Hyperetens 2004; 22(Suppl. 2): S168.Makris Th, Papazachou O, Papadopoulos D. Circadian rhythm affects unfavourably haemostasis balance parameters in untreated hypertensive patients. J Hyperetens 2004; 22(Suppl. 2): S168.Plantinga Y, Ghiadoril L, Franzoni F, Galetta F. Regular phisical activity prevents age-related decline in plasma antioxidant capacity and endothelium-dependent vasodilatation of conduit artery. J Hypertens 2004; 22(Suppl. 2): S50.Plantinga Y, Ghiadoril L, Franzoni F, Galetta F. Regular phisical activity prevents age-related decline in plasma antioxidant capacity and endothelium-dependent vasodilatation of conduit artery. J Hypertens 2004; 22(Suppl. 2): S50.Zervoudaki A, Vysssoulis GP, Karpanou EA. Relation of metabolic syndrome to albuminuria and the effect of smoking in hypertensive patients. J Hypertens 2004; 22(Suppl. 2): S228.Zervoudaki A, Vysssoulis GP, Karpanou EA. Relation of metabolic syndrome to albuminuria and the effect of smoking in hypertensive patients. J Hypertens 2004; 22(Suppl. 2): S228.

The authors declare that there are no conflicts of interest present.